Unicycive Therapeutics, Inc. Profile Avatar - Palmy Investing

Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for …

Biotechnology
US, Los Altos [HQ]
Growth Rates · Payout · Yield

Dividends Over Time

  • Records
  • Forecasts [Soon]
Growth Rates
0.00% YoY
0.00% 3Yr
0.00% 5Yr
0.00% 10Yr
Key Metrics
- -% TTM Yield
- - Average Days Gap
Series
% - - Yield
0.00% Payout Ratio
Cash Amount Pay Date
Cash Amount Pay Date
End of UNCY's Analysis
CIK: 1766140 CUSIP: 90466Y103 ISIN: US90466Y1038 LEI: - UEI: -
Secondary Listings
UNCY has no secondary listings inside our databases.